Rein Therapeutics, Inc. (RNTX) Form 10-Q — Aug 14, 2026
Rein Therapeutics reported a Q2 2026 net loss of $6.4 million, or $0.10 per share, versus a $6.8 million loss a year earlier, with no revenue and an accumulated deficit of $413.5 million. R&D spending fell to $3.6 million from $4.3 million, mainly on CRO service timing. The quarter's defining event was a May 2026 underwritten offering of 57.5 million shares at $1.00 per share that raised $57.5 million gross and $53.1 million net, lifting cash, cash equivalents and investments to $43.6 million. Management says these funds are sufficient to operate into the first quarter of 2028 and to complete the Phase 2 RENEW trial of LTI-03.
Key figures
- Revenue
- 0
- Total Assets
- 65973000
- Cash Position
- $43.6 million (cash, cash equivalents and investments)
- Gross Proceeds
- 57500000
- Offering Price
- 1
- Shares Offered
- 57500000
- Shares Outstanding
- 86267032
- Runway
- into Q1 2028
- Ga Expense Q2
- 2438000
- Rd Expense Q2
- 3638000
- Offering Expenses
- 4401000
- Total Liabilities
- 10769000
- Accumulated Deficit
- 413484000
- Warrant Liabilities
- 3701000
- Interim Data Expected
- Q4 2026
- Long Term Investments
- 2980000
- Short Term Investments
- 32105000
- Cash And Cash Equivalents
- 8542000
- Phase2 Enrollment Target
- 120
- Authorized Share Increase
- 100,000,000 to 200,000,000 (approved July 20, 2026)
- Net Proceeds May2026 Offering
- 53099000
- Cro Master Services Contracted
- 20800000
- Notes Principal Repaid May2026
- 5375000
- Shares Issuable From Warrants Options Preferred
- 27369336
Price after filing
Close on the filing date to close N calendar days later (from $0.81). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.